Laman UtamaPHS • FRA
add
Photocure ASA
Tutup sebelumnya
€4.20
Julat hari
€4.16 - €4.16
Julat tahun
€4.01 - €6.13
Nisbah P/E
-
Hasil dividen
-
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (NOK) | Jun 2024info | Perubahan T/T |
|---|---|---|
Hasil | 145.45J | 0.78% |
Perbelanjaan pengendalian | 117.16J | -2.85% |
Pendapatan bersih | 12.33J | 186.06% |
Margin untung bersih | 8.48 | 183.61% |
Pendapatan bagi setiap syer | 0.45 | 181.25% |
EBITDA | 27.85J | 19.06% |
Kadar cukai berkesan | 23.70% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (NOK) | Jun 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 266.99J | 3.11% |
Jumlah aset | 713.58J | 0.99% |
Jumlah liabiliti | 213.92J | -10.51% |
Jumlah ekuiti | 499.66J | — |
Syer tertunggak | 27.11J | — |
Harga kepada buku | 0.23 | — |
Pulangan pada aset | 7.23% | — |
Pulangan pada modal | 10.18% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (NOK) | Jun 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 12.33J | 186.06% |
Tunai daripada operasi | 19.52J | -32.96% |
Tunai daripada pelaburan | 472.00K | 265.89% |
Tunai daripada pembiayaan | -11.27J | 31.02% |
Perubahan bersih dalam tunai | 8.72J | -32.43% |
Aliran tunai bebas | 5.25J | -65.93% |
Perihal
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy. Wikipedia
Diasaskan
1993
Tapak web
Pekerja
102
